Yarrow Bioscience (YARW) Receivables (2017 - 2023)

Yarrow Bioscience (YARW) has reported Receivables for 7 consecutive years, with $250000.0 the latest figure, recorded in Q3 2023.

• For the quarter ending Q3 2023, Receivables fell 46.92% year-over-year to $250000.0; the trailing twelve-month figure through Sep 2023 stood at $250000.0 (down 46.92% YoY), and the FY2022 full-year result was $173000.0, down 98.68% from the prior year.
• Receivables climbed to $250000.0 in Q3 2023 per YARW's latest filing, from $234000.0 in the prior quarter.
• Across five years, Receivables topped out at $21.6 million in Q4 2020 and bottomed at $105000.0 in Q1 2023.
• Historically, Receivables has averaged $7.9 million across 5 years, with a median of $4.4 million in 2020.
• The sharpest annual moves came in 2020 and 2022: Receivables soared 15914.07% in 2020, then sank 98.68% in 2022.
• Over 5 years, Receivables stood at $135000.0 in 2019, then jumped by 15914.07% to $21.6 million in 2020, then plunged by 39.48% to $13.1 million in 2021, then tumbled by 98.68% to $173000.0 in 2022, then soared by 44.51% to $250000.0 in 2023.
• According to Business Quant data, Receivables over the past three periods registered $250000.0, $234000.0, and $105000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.